Mycovia Pharmaceuticals Inc. announced that Jiangsu Hengrui Pharmaceuticals Co. Ltd. has commercially launched VIVJOA (oteseconazole) in China, making available an innovative oral azole antifungal indicated for the treatment of severe vulvovaginal candidiasis (VVC). VIVJOA is contraindicated for females of reproductive potential, pregnant and lactating women, and patients with known hypersensitivity to active ingredients, excipients, and azoles.

Oteseconazole is designed to selectively inhibit fungal CYP51, which is required for fungal cell wall integrity. Due to its chemical structure, oteseconazole has a lower affinity for human CYP enzymes as compared to fungal CYP enzymes. In April 2022, the U.S. Food and Drug Administration (FDA) approved VIVJOA (oteseconazole") Capsules as the first medication for Recurrent Vulvovaginal Candidiasis (RVVC, or chronic yeast infection).

VIVJOA is currently available in the U.S. at over 300 Walgreens Community Specialty Pharmacies.